FDA Approves Lumipulse Blood Test to Aid Alzheimer’s Diagnosis
The U.S. Food and Drug Administration (FDA) has approved the Lumipulse blood test, the first of its kind, to aid in the diagnosis of Alzheimer's disease. This marks a significant advancement, offering a less invasive and more accessible option compared…
Terre Haute, IN, October 16, 2026 —
The U.S. Food and Drug Administration has approved the Lumipulse blood test to aid in the diagnosis of Alzheimer’s disease, marking the first approval of its kind, according to the information provided.
The test offers a blood-based option that is described as less invasive and more accessible than traditional approaches such as PET scans and spinal taps. Its approval is expected to improve early detection and access to treatment, although no specific details about those anticipated effects were provided.
The approval is for aiding diagnosis. The information available does not say that the test replaces PET scans, spinal taps or other methods, or that it can diagnose Alzheimer’s disease on its own. It also does not provide details about how the test works, who it is intended for, or how clinicians are expected to use its results.
No approval date, performance data, or information about the test’s availability was provided. The name of the manufacturer was also not included. Those details would help clarify how the test may fit into diagnostic care and when patients and clinicians could access it.
The approval represents a new blood-test option in Alzheimer’s diagnosis. Its practical impact will depend on details not included in the available information, including how it is used in care and whether it changes access to evaluation or treatment. For now, the stated purpose is to aid diagnosis, with improved early detection and treatment access described as expected outcomes.
Story summarized from the original created by Heather Graf on www.wthitv.com, see more information here.
Media gallery
